Platinum Equity to acquire Energy Distribution Partners after 45 acquisitions and threefold EBITDA growth
Senores Pharmaceuticals (SENORES) targets 3.2bn annual manufacturing units, yet 50% to 70% utilisation raises a bigger question
Aspen Neuroscience (ASPE) prices $140.6m IPO at $15 as Parkinson’s therapy enters pivotal development phase
Read More Pharma Industry News Denifanstat phase 3 acne trial success positions Ascletis for China NDA submission in 2026 Find out how Denifanstat’s Phase 3 acne trial success positions Ascletis Pharma for a 2026 China NDA submission and reshapes the acne-therapy market. bySoujanya RaviOctober 24, 2025